nodes	percent_of_prediction	percent_of_DWPC	metapath
Methsuximide—CYP2C19—Bortezomib—hematologic cancer	0.0674	0.201	CbGbCtD
Methsuximide—CYP2C19—Thalidomide—hematologic cancer	0.0587	0.175	CbGbCtD
Methsuximide—CYP2C19—Teniposide—hematologic cancer	0.056	0.167	CbGbCtD
Methsuximide—CYP2C19—Ifosfamide—hematologic cancer	0.0517	0.154	CbGbCtD
Methsuximide—CYP2C19—Imatinib—hematologic cancer	0.0494	0.147	CbGbCtD
Methsuximide—CYP2C19—Prednisone—hematologic cancer	0.0325	0.0968	CbGbCtD
Methsuximide—CYP2C19—Dexamethasone—hematologic cancer	0.0203	0.0604	CbGbCtD
Methsuximide—Phenobarbital—ABCC3—hematologic cancer	0.000605	0.353	CrCbGaD
Methsuximide—CACNA1H—Developmental Biology—CCND3—hematologic cancer	0.000312	0.00156	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—RAC2—hematologic cancer	0.000311	0.00156	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—hematologic cancer	0.000307	0.00154	CbGpPWpGaD
Methsuximide—CYP2C19—Constitutive Androstane Receptor Pathway—FOXO1—hematologic cancer	0.000306	0.00153	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—RAC2—hematologic cancer	0.000301	0.00151	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—HSP90AA1—hematologic cancer	0.000301	0.00151	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—NCOA3—hematologic cancer	0.000297	0.00149	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—HSP90AA1—hematologic cancer	0.000292	0.00146	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—HSP90AA1—hematologic cancer	0.000292	0.00146	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—NCAM1—hematologic cancer	0.000289	0.00145	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—NCOA3—hematologic cancer	0.000288	0.00144	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—NCAM1—hematologic cancer	0.00028	0.0014	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—HRAS—hematologic cancer	0.000275	0.00138	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—MAPK3—hematologic cancer	0.000274	0.00137	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—CTNNA1—hematologic cancer	0.000274	0.00137	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—GRB2—hematologic cancer	0.000272	0.00136	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—HRAS—hematologic cancer	0.000266	0.00133	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—TGFB1—hematologic cancer	0.000265	0.00133	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—CTNNA1—hematologic cancer	0.000265	0.00133	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—GRB2—hematologic cancer	0.000263	0.00132	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—GRB2—hematologic cancer	0.000263	0.00132	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—IL6—hematologic cancer	0.000263	0.00132	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MET—hematologic cancer	0.000263	0.00131	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—ABL1—hematologic cancer	0.000261	0.00131	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—SLC35B2—hematologic cancer	0.000257	0.00129	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—IL6—hematologic cancer	0.000255	0.00127	CbGpPWpGaD
Methsuximide—CYP2C19—Metapathway biotransformation—EPHX1—hematologic cancer	0.000253	0.00127	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—ABL1—hematologic cancer	0.000253	0.00127	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—ABL1—hematologic cancer	0.000253	0.00127	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—PTPRC—hematologic cancer	0.000246	0.00123	CbGpPWpGaD
Methsuximide—Eosinophilia—Epirubicin—hematologic cancer	0.000244	0.000527	CcSEcCtD
Methsuximide—Abdominal pain—Vincristine—hematologic cancer	0.000244	0.000527	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—PTPN11—hematologic cancer	0.000243	0.00122	CbGpPWpGaD
Methsuximide—Feeling abnormal—Gemcitabine—hematologic cancer	0.000241	0.000521	CcSEcCtD
Methsuximide—Dizziness—Vinorelbine—hematologic cancer	0.000241	0.000521	CcSEcCtD
Methsuximide—Nausea—Lenalidomide—hematologic cancer	0.000241	0.000521	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—HES1—hematologic cancer	0.000239	0.0012	CbGpPWpGaD
Methsuximide—Urticaria—Mitoxantrone—hematologic cancer	0.000239	0.000516	CcSEcCtD
Methsuximide—Anorexia—Etoposide—hematologic cancer	0.000238	0.000515	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—PTPRC—hematologic cancer	0.000238	0.00119	CbGpPWpGaD
Methsuximide—Diarrhoea—Thiotepa—hematologic cancer	0.000238	0.000515	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—NCOR1—hematologic cancer	0.000238	0.00119	CbGpPWpGaD
Methsuximide—Abdominal pain—Mitoxantrone—hematologic cancer	0.000237	0.000513	CcSEcCtD
Methsuximide—Abdominal pain—Irinotecan—hematologic cancer	0.000237	0.000513	CcSEcCtD
Methsuximide—Nausea—Hydroxyurea—hematologic cancer	0.000237	0.000513	CcSEcCtD
Methsuximide—Vomiting—Bortezomib—hematologic cancer	0.000237	0.000513	CcSEcCtD
Methsuximide—Decreased appetite—Cisplatin—hematologic cancer	0.000237	0.000513	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Cisplatin—hematologic cancer	0.000235	0.000509	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—CREB1—hematologic cancer	0.000235	0.00118	CbGpPWpGaD
Methsuximide—Vomiting—Bleomycin—hematologic cancer	0.000235	0.000509	CcSEcCtD
Methsuximide—Rash—Bortezomib—hematologic cancer	0.000235	0.000509	CcSEcCtD
Methsuximide—Dermatitis—Bortezomib—hematologic cancer	0.000235	0.000508	CcSEcCtD
Methsuximide—Drowsiness—Methotrexate—hematologic cancer	0.000235	0.000507	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—JAK1—hematologic cancer	0.000234	0.00117	CbGpPWpGaD
Methsuximide—Pancytopenia—Epirubicin—hematologic cancer	0.000234	0.000506	CcSEcCtD
Methsuximide—Headache—Bortezomib—hematologic cancer	0.000234	0.000505	CcSEcCtD
Methsuximide—Rash—Bleomycin—hematologic cancer	0.000233	0.000505	CcSEcCtD
Methsuximide—Dermatitis—Bleomycin—hematologic cancer	0.000233	0.000504	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Methotrexate—hematologic cancer	0.000233	0.000503	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—FOXO1—hematologic cancer	0.000232	0.00116	CbGpPWpGaD
Methsuximide—Vomiting—Vinorelbine—hematologic cancer	0.000232	0.000501	CcSEcCtD
Methsuximide—Diarrhoea—Thalidomide—hematologic cancer	0.00023	0.000498	CcSEcCtD
Methsuximide—Dizziness—Thiotepa—hematologic cancer	0.00023	0.000497	CcSEcCtD
Methsuximide—Rash—Vinorelbine—hematologic cancer	0.00023	0.000497	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—IL6R—hematologic cancer	0.00023	0.00115	CbGpPWpGaD
Methsuximide—Dermatitis—Vinorelbine—hematologic cancer	0.000229	0.000496	CcSEcCtD
Methsuximide—Headache—Vinorelbine—hematologic cancer	0.000228	0.000493	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—JAK1—hematologic cancer	0.000227	0.00114	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—JAK1—hematologic cancer	0.000227	0.00114	CbGpPWpGaD
Methsuximide—Eosinophilia—Doxorubicin—hematologic cancer	0.000226	0.000488	CcSEcCtD
Methsuximide—Feeling abnormal—Cisplatin—hematologic cancer	0.000225	0.000486	CcSEcCtD
Methsuximide—Haematuria—Methotrexate—hematologic cancer	0.000224	0.000484	CcSEcCtD
Methsuximide—Insomnia—Prednisolone—hematologic cancer	0.000223	0.000482	CcSEcCtD
Methsuximide—Weight decreased—Epirubicin—hematologic cancer	0.000223	0.000482	CcSEcCtD
Methsuximide—Dizziness—Thalidomide—hematologic cancer	0.000222	0.000481	CcSEcCtD
Methsuximide—Somnolence—Etoposide—hematologic cancer	0.000222	0.00048	CcSEcCtD
Methsuximide—Nausea—Bortezomib—hematologic cancer	0.000222	0.000479	CcSEcCtD
Methsuximide—Vomiting—Thiotepa—hematologic cancer	0.000221	0.000478	CcSEcCtD
Methsuximide—Diarrhoea—Carmustine—hematologic cancer	0.000221	0.000478	CcSEcCtD
Methsuximide—Nausea—Bleomycin—hematologic cancer	0.00022	0.000475	CcSEcCtD
Methsuximide—Drowsiness—Epirubicin—hematologic cancer	0.00022	0.000475	CcSEcCtD
Methsuximide—Rash—Thiotepa—hematologic cancer	0.000219	0.000474	CcSEcCtD
Methsuximide—Dermatitis—Thiotepa—hematologic cancer	0.000219	0.000474	CcSEcCtD
Methsuximide—Diarrhoea—Alitretinoin—hematologic cancer	0.000219	0.000474	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—MAP2K1—hematologic cancer	0.000219	0.0011	CbGpPWpGaD
Methsuximide—Headache—Thiotepa—hematologic cancer	0.000218	0.000471	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Epirubicin—hematologic cancer	0.000218	0.000471	CcSEcCtD
Methsuximide—Decreased appetite—Etoposide—hematologic cancer	0.000217	0.00047	CcSEcCtD
Methsuximide—Diarrhoea—Ifosfamide—hematologic cancer	0.000216	0.000468	CcSEcCtD
Methsuximide—Pancytopenia—Doxorubicin—hematologic cancer	0.000216	0.000468	CcSEcCtD
Methsuximide—Nausea—Vinorelbine—hematologic cancer	0.000216	0.000468	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Etoposide—hematologic cancer	0.000216	0.000466	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—HSP90AA1—hematologic cancer	0.000215	0.00108	CbGpPWpGaD
Methsuximide—Vomiting—Thalidomide—hematologic cancer	0.000214	0.000462	CcSEcCtD
Methsuximide—Dizziness—Carmustine—hematologic cancer	0.000214	0.000462	CcSEcCtD
Methsuximide—Constipation—Etoposide—hematologic cancer	0.000214	0.000462	CcSEcCtD
Methsuximide—Rash—Thalidomide—hematologic cancer	0.000212	0.000459	CcSEcCtD
Methsuximide—Dermatitis—Thalidomide—hematologic cancer	0.000212	0.000458	CcSEcCtD
Methsuximide—Dizziness—Alitretinoin—hematologic cancer	0.000212	0.000458	CcSEcCtD
Methsuximide—Diarrhoea—Vincristine—hematologic cancer	0.000211	0.000456	CcSEcCtD
Methsuximide—Headache—Thalidomide—hematologic cancer	0.000211	0.000456	CcSEcCtD
Methsuximide—Haematuria—Epirubicin—hematologic cancer	0.000209	0.000453	CcSEcCtD
Methsuximide—Dizziness—Ifosfamide—hematologic cancer	0.000209	0.000452	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—HSP90AA1—hematologic cancer	0.000208	0.00104	CbGpPWpGaD
Methsuximide—Ketazolam—ALB—hematologic cancer	0.000207	0.121	CrCbGaD
Methsuximide—Vision blurred—Prednisone—hematologic cancer	0.000207	0.000447	CcSEcCtD
Methsuximide—Nausea—Thiotepa—hematologic cancer	0.000207	0.000447	CcSEcCtD
Methsuximide—Weight decreased—Doxorubicin—hematologic cancer	0.000206	0.000446	CcSEcCtD
Methsuximide—Feeling abnormal—Etoposide—hematologic cancer	0.000206	0.000445	CcSEcCtD
Methsuximide—Diarrhoea—Irinotecan—hematologic cancer	0.000206	0.000444	CcSEcCtD
Methsuximide—Diarrhoea—Mitoxantrone—hematologic cancer	0.000206	0.000444	CcSEcCtD
Methsuximide—Vomiting—Carmustine—hematologic cancer	0.000205	0.000444	CcSEcCtD
Methsuximide—Insomnia—Triamcinolone—hematologic cancer	0.000205	0.000443	CcSEcCtD
Methsuximide—Gastrointestinal pain—Etoposide—hematologic cancer	0.000204	0.000442	CcSEcCtD
Methsuximide—Dizziness—Vincristine—hematologic cancer	0.000204	0.000441	CcSEcCtD
Methsuximide—Rash—Carmustine—hematologic cancer	0.000204	0.00044	CcSEcCtD
Methsuximide—Dermatitis—Carmustine—hematologic cancer	0.000204	0.00044	CcSEcCtD
Methsuximide—Vomiting—Alitretinoin—hematologic cancer	0.000204	0.00044	CcSEcCtD
Methsuximide—Drowsiness—Doxorubicin—hematologic cancer	0.000203	0.000439	CcSEcCtD
Methsuximide—Feeling abnormal—Prednisolone—hematologic cancer	0.000203	0.000439	CcSEcCtD
Methsuximide—Headache—Carmustine—hematologic cancer	0.000202	0.000438	CcSEcCtD
Methsuximide—Rash—Alitretinoin—hematologic cancer	0.000202	0.000436	CcSEcCtD
Methsuximide—Dermatitis—Alitretinoin—hematologic cancer	0.000202	0.000436	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Doxorubicin—hematologic cancer	0.000201	0.000436	CcSEcCtD
Methsuximide—Vomiting—Ifosfamide—hematologic cancer	0.000201	0.000435	CcSEcCtD
Methsuximide—Headache—Alitretinoin—hematologic cancer	0.000201	0.000434	CcSEcCtD
Methsuximide—Diarrhoea—Gemcitabine—hematologic cancer	0.0002	0.000433	CcSEcCtD
Methsuximide—Nausea—Thalidomide—hematologic cancer	0.0002	0.000432	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—JAK2—hematologic cancer	0.0002	0.000999	CbGpPWpGaD
Methsuximide—Rash—Ifosfamide—hematologic cancer	0.000199	0.000431	CcSEcCtD
Methsuximide—Dermatitis—Ifosfamide—hematologic cancer	0.000199	0.000431	CcSEcCtD
Methsuximide—Erythema multiforme—Methotrexate—hematologic cancer	0.000199	0.000431	CcSEcCtD
Methsuximide—Dizziness—Irinotecan—hematologic cancer	0.000199	0.000429	CcSEcCtD
Methsuximide—Urticaria—Etoposide—hematologic cancer	0.000199	0.000429	CcSEcCtD
Methsuximide—Ketazolam—ABCB1—hematologic cancer	0.000198	0.115	CrCbGaD
Methsuximide—Abdominal pain—Etoposide—hematologic cancer	0.000198	0.000427	CcSEcCtD
Methsuximide—Vomiting—Vincristine—hematologic cancer	0.000196	0.000424	CcSEcCtD
Methsuximide—Anorexia—Dexamethasone—hematologic cancer	0.000196	0.000424	CcSEcCtD
Methsuximide—Anorexia—Betamethasone—hematologic cancer	0.000196	0.000424	CcSEcCtD
Methsuximide—Urticaria—Prednisolone—hematologic cancer	0.000196	0.000423	CcSEcCtD
Methsuximide—Rash—Vincristine—hematologic cancer	0.000194	0.00042	CcSEcCtD
Methsuximide—Dermatitis—Vincristine—hematologic cancer	0.000194	0.00042	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—GRB2—hematologic cancer	0.000194	0.000971	CbGpPWpGaD
Methsuximide—Haematuria—Doxorubicin—hematologic cancer	0.000194	0.000419	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—MET—hematologic cancer	0.000194	0.000969	CbGpPWpGaD
Methsuximide—Headache—Vincristine—hematologic cancer	0.000193	0.000418	CcSEcCtD
Methsuximide—Nausea—Carmustine—hematologic cancer	0.000192	0.000415	CcSEcCtD
Methsuximide—Vomiting—Mitoxantrone—hematologic cancer	0.000191	0.000413	CcSEcCtD
Methsuximide—Vomiting—Irinotecan—hematologic cancer	0.000191	0.000413	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—MAPK14—hematologic cancer	0.00019	0.000953	CbGpPWpGaD
Methsuximide—Nausea—Alitretinoin—hematologic cancer	0.00019	0.000411	CcSEcCtD
Methsuximide—Rash—Mitoxantrone—hematologic cancer	0.000189	0.000409	CcSEcCtD
Methsuximide—Rash—Irinotecan—hematologic cancer	0.000189	0.000409	CcSEcCtD
Methsuximide—Dermatitis—Mitoxantrone—hematologic cancer	0.000189	0.000409	CcSEcCtD
Methsuximide—Dermatitis—Irinotecan—hematologic cancer	0.000189	0.000409	CcSEcCtD
Methsuximide—Headache—Irinotecan—hematologic cancer	0.000188	0.000407	CcSEcCtD
Methsuximide—Headache—Mitoxantrone—hematologic cancer	0.000188	0.000407	CcSEcCtD
Methsuximide—Nausea—Ifosfamide—hematologic cancer	0.000188	0.000406	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—GRB2—hematologic cancer	0.000188	0.00094	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MET—hematologic cancer	0.000188	0.000939	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—CDK4—hematologic cancer	0.000187	0.000938	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MET—hematologic cancer	0.000187	0.000938	CbGpPWpGaD
Methsuximide—Feeling abnormal—Triamcinolone—hematologic cancer	0.000187	0.000404	CcSEcCtD
Methsuximide—Diarrhoea—Cisplatin—hematologic cancer	0.000187	0.000403	CcSEcCtD
Methsuximide—Erythema multiforme—Epirubicin—hematologic cancer	0.000186	0.000403	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—ABL1—hematologic cancer	0.000186	0.000933	CbGpPWpGaD
Methsuximide—Vomiting—Gemcitabine—hematologic cancer	0.000186	0.000402	CcSEcCtD
Methsuximide—Insomnia—Betamethasone—hematologic cancer	0.000186	0.000402	CcSEcCtD
Methsuximide—Insomnia—Dexamethasone—hematologic cancer	0.000186	0.000402	CcSEcCtD
Methsuximide—Rash—Gemcitabine—hematologic cancer	0.000185	0.000399	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—AKT1—hematologic cancer	0.000184	0.000923	CbGpPWpGaD
Methsuximide—Dermatitis—Gemcitabine—hematologic cancer	0.000184	0.000399	CcSEcCtD
Methsuximide—Headache—Gemcitabine—hematologic cancer	0.000183	0.000396	CcSEcCtD
Methsuximide—Nausea—Vincristine—hematologic cancer	0.000183	0.000396	CcSEcCtD
Methsuximide—Pethidine—ALB—hematologic cancer	0.000181	0.106	CrCbGaD
Methsuximide—CACNA1H—Developmental Biology—ABL1—hematologic cancer	0.000181	0.000903	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—NOTCH1—hematologic cancer	0.00018	0.000903	CbGpPWpGaD
Methsuximide—Urticaria—Triamcinolone—hematologic cancer	0.00018	0.000389	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—PTPN11—hematologic cancer	0.000179	0.000897	CbGpPWpGaD
Methsuximide—Decreased appetite—Dexamethasone—hematologic cancer	0.000179	0.000386	CcSEcCtD
Methsuximide—Decreased appetite—Betamethasone—hematologic cancer	0.000179	0.000386	CcSEcCtD
Methsuximide—Nausea—Irinotecan—hematologic cancer	0.000178	0.000386	CcSEcCtD
Methsuximide—Nausea—Mitoxantrone—hematologic cancer	0.000178	0.000386	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Dexamethasone—hematologic cancer	0.000178	0.000384	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Betamethasone—hematologic cancer	0.000178	0.000384	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—HES1—hematologic cancer	0.000176	0.000882	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—NCOR1—hematologic cancer	0.000175	0.000877	CbGpPWpGaD
Methsuximide—Nausea—Gemcitabine—hematologic cancer	0.000174	0.000376	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—CREB1—hematologic cancer	0.000174	0.000869	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—PTPN11—hematologic cancer	0.000173	0.000868	CbGpPWpGaD
Methsuximide—Vomiting—Cisplatin—hematologic cancer	0.000173	0.000375	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—PTPN11—hematologic cancer	0.000173	0.000868	CbGpPWpGaD
Methsuximide—Vision blurred—Methotrexate—hematologic cancer	0.000173	0.000374	CcSEcCtD
Methsuximide—Erythema multiforme—Doxorubicin—hematologic cancer	0.000172	0.000373	CcSEcCtD
Methsuximide—Rash—Cisplatin—hematologic cancer	0.000172	0.000372	CcSEcCtD
Methsuximide—Dermatitis—Cisplatin—hematologic cancer	0.000172	0.000371	CcSEcCtD
Methsuximide—Diarrhoea—Etoposide—hematologic cancer	0.000171	0.00037	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—FOXO1—hematologic cancer	0.000171	0.000855	CbGpPWpGaD
Methsuximide—Anorexia—Prednisone—hematologic cancer	0.000171	0.000369	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—HES1—hematologic cancer	0.000171	0.000854	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—NCOR1—hematologic cancer	0.00017	0.000849	CbGpPWpGaD
Methsuximide—Feeling abnormal—Betamethasone—hematologic cancer	0.000169	0.000366	CcSEcCtD
Methsuximide—Feeling abnormal—Dexamethasone—hematologic cancer	0.000169	0.000366	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—IL6R—hematologic cancer	0.000169	0.000847	CbGpPWpGaD
Methsuximide—Tension—Epirubicin—hematologic cancer	0.000168	0.000364	CcSEcCtD
Methsuximide—Gastrointestinal pain—Dexamethasone—hematologic cancer	0.000168	0.000364	CcSEcCtD
Methsuximide—Gastrointestinal pain—Betamethasone—hematologic cancer	0.000168	0.000364	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—CREB1—hematologic cancer	0.000168	0.000841	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—CREB1—hematologic cancer	0.000168	0.000841	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—JAK1—hematologic cancer	0.000167	0.000837	CbGpPWpGaD
Methsuximide—Nervousness—Epirubicin—hematologic cancer	0.000167	0.00036	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—GSTO1—hematologic cancer	0.000166	0.000829	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—FOXO1—hematologic cancer	0.000165	0.000828	CbGpPWpGaD
Methsuximide—Dizziness—Etoposide—hematologic cancer	0.000165	0.000357	CcSEcCtD
Methsuximide—Leukopenia—Methotrexate—hematologic cancer	0.000164	0.000355	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—IL6R—hematologic cancer	0.000164	0.000821	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—IL6R—hematologic cancer	0.000164	0.00082	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—CREBBP—hematologic cancer	0.000164	0.000819	CbGpPWpGaD
Methsuximide—Urticaria—Betamethasone—hematologic cancer	0.000163	0.000353	CcSEcCtD
Methsuximide—Urticaria—Dexamethasone—hematologic cancer	0.000163	0.000353	CcSEcCtD
Methsuximide—CYP2C19—Metapathway biotransformation—GSTO1—hematologic cancer	0.000163	0.000817	CbGpPWpGaD
Methsuximide—Dizziness—Prednisolone—hematologic cancer	0.000163	0.000352	CcSEcCtD
Methsuximide—Abdominal pain—Betamethasone—hematologic cancer	0.000163	0.000351	CcSEcCtD
Methsuximide—Abdominal pain—Dexamethasone—hematologic cancer	0.000163	0.000351	CcSEcCtD
Methsuximide—Nausea—Cisplatin—hematologic cancer	0.000162	0.00035	CcSEcCtD
Methsuximide—Insomnia—Prednisone—hematologic cancer	0.000162	0.00035	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—JAK1—hematologic cancer	0.000162	0.000811	CbGpPWpGaD
Methsuximide—Vision blurred—Epirubicin—hematologic cancer	0.000162	0.00035	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—MAP2K1—hematologic cancer	0.000161	0.000808	CbGpPWpGaD
Methsuximide—Vomiting—Etoposide—hematologic cancer	0.000159	0.000343	CcSEcCtD
Methsuximide—Rash—Etoposide—hematologic cancer	0.000158	0.000341	CcSEcCtD
Methsuximide—Dermatitis—Etoposide—hematologic cancer	0.000157	0.00034	CcSEcCtD
Methsuximide—Headache—Etoposide—hematologic cancer	0.000157	0.000338	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—MAP2K1—hematologic cancer	0.000156	0.000782	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MAP2K1—hematologic cancer	0.000156	0.000782	CbGpPWpGaD
Methsuximide—Tension—Doxorubicin—hematologic cancer	0.000156	0.000337	CcSEcCtD
Methsuximide—Decreased appetite—Prednisone—hematologic cancer	0.000156	0.000337	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—UGT1A1—hematologic cancer	0.000156	0.000779	CbGpPWpGaD
Methsuximide—Rash—Prednisolone—hematologic cancer	0.000155	0.000336	CcSEcCtD
Methsuximide—Dermatitis—Prednisolone—hematologic cancer	0.000155	0.000336	CcSEcCtD
Methsuximide—Headache—Prednisolone—hematologic cancer	0.000154	0.000334	CcSEcCtD
Methsuximide—Nervousness—Doxorubicin—hematologic cancer	0.000154	0.000333	CcSEcCtD
Methsuximide—Leukopenia—Epirubicin—hematologic cancer	0.000154	0.000332	CcSEcCtD
Methsuximide—CYP2C19—Metapathway biotransformation—UGT1A1—hematologic cancer	0.000154	0.000768	CbGpPWpGaD
Methsuximide—Constipation—Prednisone—hematologic cancer	0.000153	0.000331	CcSEcCtD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PHYH—hematologic cancer	0.000153	0.000766	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—SRC—hematologic cancer	0.000152	0.00076	CbGpPWpGaD
Methsuximide—Confusional state—Methotrexate—hematologic cancer	0.000151	0.000326	CcSEcCtD
Methsuximide—Dizziness—Triamcinolone—hematologic cancer	0.00015	0.000324	CcSEcCtD
Methsuximide—Vision blurred—Doxorubicin—hematologic cancer	0.00015	0.000324	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—FGF2—hematologic cancer	0.000149	0.000744	CbGpPWpGaD
Methsuximide—Nausea—Etoposide—hematologic cancer	0.000148	0.000321	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—VEGFA—hematologic cancer	0.000148	0.00074	CbGpPWpGaD
Methsuximide—Feeling abnormal—Prednisone—hematologic cancer	0.000148	0.000319	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—JAK2—hematologic cancer	0.000147	0.000736	CbGpPWpGaD
Methsuximide—Gastrointestinal pain—Prednisone—hematologic cancer	0.000146	0.000317	CcSEcCtD
Methsuximide—Nausea—Prednisolone—hematologic cancer	0.000146	0.000316	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—NRAS—hematologic cancer	0.000146	0.000731	CbGpPWpGaD
Methsuximide—Vomiting—Triamcinolone—hematologic cancer	0.000144	0.000312	CcSEcCtD
Methsuximide—Rash—Triamcinolone—hematologic cancer	0.000143	0.000309	CcSEcCtD
Methsuximide—Dermatitis—Triamcinolone—hematologic cancer	0.000143	0.000309	CcSEcCtD
Methsuximide—Anorexia—Methotrexate—hematologic cancer	0.000143	0.000308	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—JAK2—hematologic cancer	0.000142	0.000713	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—JAK2—hematologic cancer	0.000142	0.000713	CbGpPWpGaD
Methsuximide—Urticaria—Prednisone—hematologic cancer	0.000142	0.000308	CcSEcCtD
Methsuximide—Leukopenia—Doxorubicin—hematologic cancer	0.000142	0.000307	CcSEcCtD
Methsuximide—Headache—Triamcinolone—hematologic cancer	0.000142	0.000307	CcSEcCtD
Methsuximide—Abdominal pain—Prednisone—hematologic cancer	0.000142	0.000306	CcSEcCtD
Methsuximide—Confusional state—Epirubicin—hematologic cancer	0.000141	0.000305	CcSEcCtD
Methsuximide—Diarrhoea—Betamethasone—hematologic cancer	0.000141	0.000304	CcSEcCtD
Methsuximide—Diarrhoea—Dexamethasone—hematologic cancer	0.000141	0.000304	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—MAPK14—hematologic cancer	0.00014	0.000702	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—SMPD3—hematologic cancer	0.00014	0.000701	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MAPK3—hematologic cancer	0.00014	0.0007	CbGpPWpGaD
Methsuximide—Clobazam—ABCB1—hematologic cancer	0.00014	0.0816	CrCbGaD
Methsuximide—CACNA1G—Developmental Biology—MET—hematologic cancer	0.000138	0.000692	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—CDK4—hematologic cancer	0.000138	0.000692	CbGpPWpGaD
Methsuximide—Dizziness—Betamethasone—hematologic cancer	0.000136	0.000294	CcSEcCtD
Methsuximide—Dizziness—Dexamethasone—hematologic cancer	0.000136	0.000294	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—MAPK14—hematologic cancer	0.000136	0.00068	CbGpPWpGaD
Methsuximide—Insomnia—Methotrexate—hematologic cancer	0.000135	0.000293	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—MTR—hematologic cancer	0.000135	0.000675	CbGpPWpGaD
Methsuximide—Nausea—Triamcinolone—hematologic cancer	0.000135	0.000291	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—CDK4—hematologic cancer	0.000134	0.00067	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MET—hematologic cancer	0.000134	0.00067	CbGpPWpGaD
Methsuximide—Phenytoin—ALB—hematologic cancer	0.000134	0.0779	CrCbGaD
Methsuximide—Anorexia—Epirubicin—hematologic cancer	0.000134	0.000289	CcSEcCtD
Methsuximide—Somnolence—Methotrexate—hematologic cancer	0.000133	0.000288	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—NOTCH1—hematologic cancer	0.000133	0.000666	CbGpPWpGaD
Methsuximide—Vomiting—Betamethasone—hematologic cancer	0.000131	0.000283	CcSEcCtD
Methsuximide—Vomiting—Dexamethasone—hematologic cancer	0.000131	0.000283	CcSEcCtD
Methsuximide—Confusional state—Doxorubicin—hematologic cancer	0.000131	0.000283	CcSEcCtD
Methsuximide—Decreased appetite—Methotrexate—hematologic cancer	0.00013	0.000281	CcSEcCtD
Methsuximide—Rash—Betamethasone—hematologic cancer	0.00013	0.00028	CcSEcCtD
Methsuximide—Rash—Dexamethasone—hematologic cancer	0.00013	0.00028	CcSEcCtD
Methsuximide—Dermatitis—Dexamethasone—hematologic cancer	0.00013	0.00028	CcSEcCtD
Methsuximide—Dermatitis—Betamethasone—hematologic cancer	0.00013	0.00028	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Methotrexate—hematologic cancer	0.000129	0.000279	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—NOTCH1—hematologic cancer	0.000129	0.000645	CbGpPWpGaD
Methsuximide—Headache—Dexamethasone—hematologic cancer	0.000129	0.000279	CcSEcCtD
Methsuximide—Headache—Betamethasone—hematologic cancer	0.000129	0.000279	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—GSTT1—hematologic cancer	0.000128	0.000642	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—PTPN11—hematologic cancer	0.000128	0.00064	CbGpPWpGaD
Methsuximide—Phenytoin—ABCB1—hematologic cancer	0.000128	0.0744	CrCbGaD
Methsuximide—Insomnia—Epirubicin—hematologic cancer	0.000127	0.000274	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—KRAS—hematologic cancer	0.000126	0.000629	CbGpPWpGaD
Methsuximide—Somnolence—Epirubicin—hematologic cancer	0.000125	0.000269	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—CREB1—hematologic cancer	0.000124	0.00062	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—PTPN11—hematologic cancer	0.000124	0.00062	CbGpPWpGaD
Methsuximide—Anorexia—Doxorubicin—hematologic cancer	0.000124	0.000267	CcSEcCtD
Methsuximide—Feeling abnormal—Methotrexate—hematologic cancer	0.000123	0.000267	CcSEcCtD
Methsuximide—Diarrhoea—Prednisone—hematologic cancer	0.000123	0.000265	CcSEcCtD
Methsuximide—Gastrointestinal pain—Methotrexate—hematologic cancer	0.000122	0.000265	CcSEcCtD
Methsuximide—Phenobarbital—ABCB1—hematologic cancer	0.000122	0.0713	CrCbGaD
Methsuximide—Nausea—Betamethasone—hematologic cancer	0.000122	0.000264	CcSEcCtD
Methsuximide—Nausea—Dexamethasone—hematologic cancer	0.000122	0.000264	CcSEcCtD
Methsuximide—Decreased appetite—Epirubicin—hematologic cancer	0.000122	0.000263	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Epirubicin—hematologic cancer	0.000121	0.000261	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—IL6R—hematologic cancer	0.000121	0.000605	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—CREBBP—hematologic cancer	0.000121	0.000604	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—CREB1—hematologic cancer	0.00012	0.0006	CbGpPWpGaD
Methsuximide—Constipation—Epirubicin—hematologic cancer	0.00012	0.000259	CcSEcCtD
Methsuximide—Urticaria—Methotrexate—hematologic cancer	0.000119	0.000257	CcSEcCtD
Methsuximide—Dizziness—Prednisone—hematologic cancer	0.000118	0.000256	CcSEcCtD
Methsuximide—Abdominal pain—Methotrexate—hematologic cancer	0.000118	0.000256	CcSEcCtD
Methsuximide—Insomnia—Doxorubicin—hematologic cancer	0.000117	0.000253	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—IL6R—hematologic cancer	0.000117	0.000586	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—CREBBP—hematologic cancer	0.000117	0.000585	CbGpPWpGaD
Methsuximide—Feeling abnormal—Epirubicin—hematologic cancer	0.000115	0.00025	CcSEcCtD
Methsuximide—Somnolence—Doxorubicin—hematologic cancer	0.000115	0.000249	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—MAP2K1—hematologic cancer	0.000115	0.000576	CbGpPWpGaD
Methsuximide—Gastrointestinal pain—Epirubicin—hematologic cancer	0.000115	0.000248	CcSEcCtD
Methsuximide—Vomiting—Prednisone—hematologic cancer	0.000114	0.000246	CcSEcCtD
Methsuximide—Rash—Prednisone—hematologic cancer	0.000113	0.000244	CcSEcCtD
Methsuximide—Dermatitis—Prednisone—hematologic cancer	0.000113	0.000244	CcSEcCtD
Methsuximide—Decreased appetite—Doxorubicin—hematologic cancer	0.000113	0.000244	CcSEcCtD
Methsuximide—Headache—Prednisone—hematologic cancer	0.000112	0.000243	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—SRC—hematologic cancer	0.000112	0.00056	CbGpPWpGaD
Methsuximide—Gastrointestinal disorder—Doxorubicin—hematologic cancer	0.000112	0.000242	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—MAP2K1—hematologic cancer	0.000112	0.000558	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—EP300—hematologic cancer	0.000111	0.000558	CbGpPWpGaD
Methsuximide—Urticaria—Epirubicin—hematologic cancer	0.000111	0.000241	CcSEcCtD
Methsuximide—Constipation—Doxorubicin—hematologic cancer	0.000111	0.00024	CcSEcCtD
Methsuximide—Abdominal pain—Epirubicin—hematologic cancer	0.000111	0.000239	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—FGF2—hematologic cancer	0.00011	0.000548	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—VEGFA—hematologic cancer	0.000109	0.000546	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—SRC—hematologic cancer	0.000108	0.000543	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—SRC—hematologic cancer	0.000108	0.000542	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—NRAS—hematologic cancer	0.000108	0.000539	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—HRAS—hematologic cancer	0.000107	0.000535	CbGpPWpGaD
Methsuximide—Feeling abnormal—Doxorubicin—hematologic cancer	0.000107	0.000231	CcSEcCtD
Methsuximide—Nausea—Prednisone—hematologic cancer	0.000106	0.00023	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—FGF2—hematologic cancer	0.000106	0.000531	CbGpPWpGaD
Methsuximide—Gastrointestinal pain—Doxorubicin—hematologic cancer	0.000106	0.000229	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—VEGFA—hematologic cancer	0.000106	0.000529	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—VEGFA—hematologic cancer	0.000106	0.000528	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—JAK2—hematologic cancer	0.000105	0.000525	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—STAT3—hematologic cancer	0.000105	0.000523	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—NRAS—hematologic cancer	0.000104	0.000522	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—NRAS—hematologic cancer	0.000104	0.000522	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MAPK3—hematologic cancer	0.000103	0.000516	CbGpPWpGaD
Methsuximide—Urticaria—Doxorubicin—hematologic cancer	0.000103	0.000223	CcSEcCtD
Methsuximide—Abdominal pain—Doxorubicin—hematologic cancer	0.000102	0.000221	CcSEcCtD
Methsuximide—Diarrhoea—Methotrexate—hematologic cancer	0.000102	0.000221	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—IL6—hematologic cancer	0.000102	0.000512	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—JAK2—hematologic cancer	0.000102	0.000509	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MAPK3—hematologic cancer	9.99e-05	0.0005	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MAPK3—hematologic cancer	9.98e-05	0.0005	CbGpPWpGaD
Methsuximide—Dizziness—Methotrexate—hematologic cancer	9.9e-05	0.000214	CcSEcCtD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—GBA—hematologic cancer	9.87e-05	0.000494	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—TGFB1—hematologic cancer	9.69e-05	0.000485	CbGpPWpGaD
Methsuximide—Diarrhoea—Epirubicin—hematologic cancer	9.58e-05	0.000207	CcSEcCtD
Methsuximide—Vomiting—Methotrexate—hematologic cancer	9.52e-05	0.000206	CcSEcCtD
Methsuximide—Rash—Methotrexate—hematologic cancer	9.44e-05	0.000204	CcSEcCtD
Methsuximide—Dermatitis—Methotrexate—hematologic cancer	9.43e-05	0.000204	CcSEcCtD
Methsuximide—Headache—Methotrexate—hematologic cancer	9.38e-05	0.000203	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—KRAS—hematologic cancer	9.27e-05	0.000464	CbGpPWpGaD
Methsuximide—Dizziness—Epirubicin—hematologic cancer	9.26e-05	0.0002	CcSEcCtD
Methsuximide—CACNA1I—Developmental Biology—TNF—hematologic cancer	9.05e-05	0.000453	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—KRAS—hematologic cancer	8.98e-05	0.000449	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—KRAS—hematologic cancer	8.97e-05	0.000449	CbGpPWpGaD
Methsuximide—Vomiting—Epirubicin—hematologic cancer	8.91e-05	0.000193	CcSEcCtD
Methsuximide—CYP2C19—Biological oxidations—GSTP1—hematologic cancer	8.9e-05	0.000445	CbGpPWpGaD
Methsuximide—Nausea—Methotrexate—hematologic cancer	8.89e-05	0.000192	CcSEcCtD
Methsuximide—Diarrhoea—Doxorubicin—hematologic cancer	8.87e-05	0.000192	CcSEcCtD
Methsuximide—Rash—Epirubicin—hematologic cancer	8.83e-05	0.000191	CcSEcCtD
Methsuximide—Dermatitis—Epirubicin—hematologic cancer	8.82e-05	0.000191	CcSEcCtD
Methsuximide—CYP2C19—Metapathway biotransformation—GSTP1—hematologic cancer	8.78e-05	0.000439	CbGpPWpGaD
Methsuximide—Headache—Epirubicin—hematologic cancer	8.77e-05	0.00019	CcSEcCtD
Methsuximide—Dizziness—Doxorubicin—hematologic cancer	8.57e-05	0.000185	CcSEcCtD
Methsuximide—Nausea—Epirubicin—hematologic cancer	8.32e-05	0.00018	CcSEcCtD
Methsuximide—Vomiting—Doxorubicin—hematologic cancer	8.24e-05	0.000178	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—EP300—hematologic cancer	8.22e-05	0.000411	CbGpPWpGaD
Methsuximide—CYP2C19—Biological oxidations—GSTM1—hematologic cancer	8.18e-05	0.000409	CbGpPWpGaD
Methsuximide—Rash—Doxorubicin—hematologic cancer	8.17e-05	0.000177	CcSEcCtD
Methsuximide—Dermatitis—Doxorubicin—hematologic cancer	8.16e-05	0.000177	CcSEcCtD
Methsuximide—Headache—Doxorubicin—hematologic cancer	8.12e-05	0.000176	CcSEcCtD
Methsuximide—CYP2C19—Metapathway biotransformation—GSTM1—hematologic cancer	8.06e-05	0.000404	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—FHL2—hematologic cancer	8.04e-05	0.000402	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—SRC—hematologic cancer	7.99e-05	0.0004	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—EP300—hematologic cancer	7.96e-05	0.000398	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—HRAS—hematologic cancer	7.88e-05	0.000394	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—VEGFA—hematologic cancer	7.78e-05	0.000389	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—SRC—hematologic cancer	7.74e-05	0.000387	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—STAT3—hematologic cancer	7.7e-05	0.000386	CbGpPWpGaD
Methsuximide—Nausea—Doxorubicin—hematologic cancer	7.7e-05	0.000166	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—NRAS—hematologic cancer	7.69e-05	0.000385	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—HRAS—hematologic cancer	7.63e-05	0.000382	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—HRAS—hematologic cancer	7.63e-05	0.000382	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—IL6—hematologic cancer	7.54e-05	0.000377	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—VEGFA—hematologic cancer	7.54e-05	0.000377	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—STAT3—hematologic cancer	7.46e-05	0.000373	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—NRAS—hematologic cancer	7.44e-05	0.000373	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MAPK3—hematologic cancer	7.36e-05	0.000368	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—IL6—hematologic cancer	7.3e-05	0.000366	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—IL6—hematologic cancer	7.3e-05	0.000365	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—TGFB1—hematologic cancer	7.14e-05	0.000357	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MAPK3—hematologic cancer	7.13e-05	0.000357	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—ARNTL—hematologic cancer	7.03e-05	0.000352	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—TGFB1—hematologic cancer	6.92e-05	0.000346	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GMPS—hematologic cancer	6.82e-05	0.000341	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—FTCD—hematologic cancer	6.82e-05	0.000341	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PHYH—hematologic cancer	6.82e-05	0.000341	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—NCOR2—hematologic cancer	6.75e-05	0.000338	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—AKT1—hematologic cancer	6.73e-05	0.000337	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—TNF—hematologic cancer	6.67e-05	0.000334	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—KRAS—hematologic cancer	6.62e-05	0.000331	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—TNF—hematologic cancer	6.46e-05	0.000323	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—IDH1—hematologic cancer	6.43e-05	0.000322	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—KRAS—hematologic cancer	6.41e-05	0.000321	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—ABCC3—hematologic cancer	6.36e-05	0.000318	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SMPD3—hematologic cancer	6.24e-05	0.000312	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—SPHK1—hematologic cancer	6.22e-05	0.000311	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—hematologic cancer	5.81e-05	0.000291	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—ALOX5—hematologic cancer	5.67e-05	0.000284	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—HRAS—hematologic cancer	5.62e-05	0.000281	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—B3GAT1—hematologic cancer	5.45e-05	0.000273	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ASNS—hematologic cancer	5.45e-05	0.000273	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—DCK—hematologic cancer	5.45e-05	0.000273	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—HRAS—hematologic cancer	5.45e-05	0.000273	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—IL6—hematologic cancer	5.38e-05	0.000269	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—NCOA3—hematologic cancer	5.33e-05	0.000267	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—IL6—hematologic cancer	5.21e-05	0.000261	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—HDC—hematologic cancer	5.17e-05	0.000259	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—AKT1—hematologic cancer	4.97e-05	0.000248	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—SDC1—hematologic cancer	4.82e-05	0.000241	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—AKT1—hematologic cancer	4.81e-05	0.000241	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CDA—hematologic cancer	4.73e-05	0.000237	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PC—hematologic cancer	4.55e-05	0.000228	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GBA—hematologic cancer	4.39e-05	0.00022	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SLC35B2—hematologic cancer	4.39e-05	0.00022	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—MTAP—hematologic cancer	4.02e-05	0.000201	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—FHL2—hematologic cancer	3.58e-05	0.000179	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—AGRN—hematologic cancer	3.51e-05	0.000176	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—IDH2—hematologic cancer	3.33e-05	0.000167	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—HMMR—hematologic cancer	3.33e-05	0.000167	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	3.14e-05	0.000157	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ARNTL—hematologic cancer	3.13e-05	0.000157	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CA9—hematologic cancer	3.05e-05	0.000152	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ACP5—hematologic cancer	3.05e-05	0.000152	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NCOR2—hematologic cancer	3.01e-05	0.00015	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—IDH1—hematologic cancer	2.86e-05	0.000143	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—TXN—hematologic cancer	2.83e-05	0.000142	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ABCC3—hematologic cancer	2.83e-05	0.000142	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTO1—hematologic cancer	2.83e-05	0.000142	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SPHK1—hematologic cancer	2.77e-05	0.000139	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—UGT1A1—hematologic cancer	2.66e-05	0.000133	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SLC22A1—hematologic cancer	2.59e-05	0.00013	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CRABP1—hematologic cancer	2.59e-05	0.00013	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ALOX5—hematologic cancer	2.52e-05	0.000126	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NUP98—hematologic cancer	2.44e-05	0.000122	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ADCY7—hematologic cancer	2.37e-05	0.000119	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NCOA3—hematologic cancer	2.37e-05	0.000119	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NUP214—hematologic cancer	2.36e-05	0.000118	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	2.33e-05	0.000117	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—MTR—hematologic cancer	2.31e-05	0.000116	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ABCG2—hematologic cancer	2.31e-05	0.000116	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ENO2—hematologic cancer	2.26e-05	0.000113	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTT1—hematologic cancer	2.2e-05	0.00011	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	2.16e-05	0.000108	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SDC1—hematologic cancer	2.15e-05	0.000107	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	2.05e-05	0.000103	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	2.02e-05	0.000101	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.94e-05	9.69e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CD44—hematologic cancer	1.82e-05	9.13e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NQO1—hematologic cancer	1.82e-05	9.13e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.79e-05	8.94e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CYCS—hematologic cancer	1.73e-05	8.64e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	1.72e-05	8.58e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.54e-05	7.73e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTP1—hematologic cancer	1.52e-05	7.62e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.47e-05	7.37e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ABCB1—hematologic cancer	1.44e-05	7.21e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NCOR1—hematologic cancer	1.4e-05	7e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GSTM1—hematologic cancer	1.4e-05	7e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—MTHFR—hematologic cancer	1.24e-05	6.18e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.09e-05	5.45e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CG—hematologic cancer	1.04e-05	5.2e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CREBBP—hematologic cancer	9.63e-06	4.82e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CD—hematologic cancer	9.13e-06	4.57e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ALB—hematologic cancer	9.01e-06	4.51e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3R1—hematologic cancer	8.62e-06	4.31e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CB—hematologic cancer	7.96e-06	3.98e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PTEN—hematologic cancer	6.87e-06	3.44e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—EP300—hematologic cancer	6.56e-06	3.28e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CA—hematologic cancer	4.85e-06	2.43e-05	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—AKT1—hematologic cancer	3.96e-06	1.98e-05	CbGpPWpGaD
